| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Loss from operations | - | -6,414,518 | -7,676,922 | -4,450,289 |
| Other income | 317,066 | 319,541 | 370,165 | 428,871 |
| Pre-tax loss | - | -6,094,977 | -7,306,757 | - |
| Income tax expense | - | 0 | - | - |
| Net loss | -2,115,831 | -6,094,977 | -7,306,757 | -4,021,418 |
| Earnings per share, basic | -0.13 | -0.36 | -0.44 | -0.26 |
| Earnings per share, diluted | -0.13 | -0.36 | -0.44 | -0.26 |
| Weighted average number of shares outstanding, basic | 16,732,766 | 16,724,998 | 16,720,511 | 15,221,308 |
| Weighted average number of shares outstanding, diluted | 16,732,766 | 16,724,998 | 16,720,511 | 15,221,308 |
Coya Therapeutics, Inc. (COYA)
Coya Therapeutics, Inc. (COYA)